Solving adherence issues with prodrugs, examining whether PBMs are to blame for high drugs prices in the US, developing ...

As the approval date for Bristol Myers Squibb’s schizophrenia drug KarXT looms, a prodrug approach emerges to potentially ...

- Collaboration to leverage AbbVie's eye care expertise and Ripple's innovative drug delivery platform to develop next-generation sustained release drug delivery implants for the treatment of glaucoma ...

H.C. Wainwright analyst Oren Livnat reiterated a Buy rating on Zevra Therapeutics (ZVRA – Research Report) today and set a price target ...

Explore the latest strides in schizophrenia treatment development as 2024 heralds a pivotal year, with promising collaborations and trials.

Detailed price information for Thiogenesis Therapeutics Corp (TTI-X) from The Globe and Mail including charting and trades.

From spoiled meat to seaweed and secure software – a wide range of University of Otago research projects have secured $8 ...

From spoiled meat to seaweed and secure software – a wide range of University of Otago research projects have secured $8 ...

Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and ...

London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as ...

Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) ("Atea"), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics ...